We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comment on Tabatabaei Dakhili et al. The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase. Diabetes 2023;72:126–134.
- Authors
Reynolds, Gavin P.
- Abstract
The article focuses on the potential use of the antipsychotic diphenylbutylpiperidine (DPBP) drugs, specifically pimozide, in alleviating obesity-induced type 2 diabetes. Topics incluide DPBPs can reduce hyperglycemia by inhibiting succinyl CoA:3-ketoacid CoA transferase activity through noncanonical actions; and doses of DPBPs used in the experiments are much higher than those used in clinical settings for antipsychotic purposes of the feasibility of repurposing DPBPs for diabetes treatment.
- Subjects
DOPAMINE antagonists; DOPAMINE receptors; DIABETES; OBESITY
- Publication
Diabetes, 2023, Vol 72, Issue 5, pe5
- ISSN
0012-1797
- Publication type
Letter
- DOI
10.2337/db23-0088